Welcome to our dedicated page for Dogecoin Cash news (Ticker: CBDS), a resource for investors and traders seeking the latest updates and insights on Dogecoin Cash stock.
Dogecoin Cash Inc. (CBDS) generates news at the intersection of medical cannabis telemedicine, cannabis intellectual property, and blockchain-focused digital asset initiatives. Company announcements highlight developments across its PrestoDoctor telehealth operations, cannabis product and strain patents, and projects related to Dogecoin and meme-based tokens.
News items often cover PrestoDoctor’s expansion into additional U.S. states for medical cannabis evaluations, updates on telehealth services, and platform capabilities designed for compliance with state medical cannabis and telemedicine rules. These releases provide insight into how the company grows its medical cannabis telehealth footprint and adapts its technology to regulated healthcare environments.
Dogecoin Cash Inc. also issues news about its cannabis product development and licensing activities, including references to its patented cannabis strain Ecuadorian Sativa ("CTA") and its patented cannabis lozenge for hypertension. Such disclosures help readers understand the company’s role in cannabis genetics and dosage-form innovation.
On the blockchain side, the company publishes updates on digital asset initiatives, including the formation of Dogecoin Treasury, Inc., work on the proposed Dogecoin Protocol, and activities within MEME Coins Inc. related to DOG tokens and meme-based cryptocurrency concepts. These news releases describe patent filings, technical frameworks, and digital asset strategies involving Dogecoin and related tools.
Investors and observers can use this news feed to follow how Dogecoin Cash Inc. develops its telehealth platform, advances its cannabis IP portfolio, and pursues blockchain and digital asset projects. Regularly reviewing CBDS news can provide context on the company’s evolving mix of cannabis and blockchain-focused activities.
Dogecoin Cash (OTCQB: CBDS) has announced a definitive agreement with Bots, Inc. (BTZI) to acquire 420 million DogeCoin Cash ($DOG) tokens in exchange for 4.2 million shares of CBDS common stock. The transaction is set to close on March 1, 2025, with CBDS establishing a Binance Wallet for the token transfer.
This acquisition follows CBDS's previous purchase of 600 million $DOG from DogeSPAC, Upon completion, CBDS's total $DOG holdings will reach 1.02 billion tokens. The agreement with Bots, Inc. represents a transfer of 50% of their $DOG holdings, which currently total 840 million tokens.
The company also provided an update regarding its preferred dividend, indicating that FINRA is not expected to set an ex-dividend date, meaning only shareholders who held common shares on November 25, 2024, will likely receive the preferred shares.
Summary not available.
Summary not available.
Summary not available.
Cannabis Sativa, Inc. (OTCQB:CBDS) announced that PrestoDoctor will conduct on-site medical cannabis evaluations at the 9th annual Pennsylvania Cannabis Festival, Pocono 420, at Pocono Raceway on April 22-23. COO Rob Tankson emphasized the ease of the medical evaluation process during the event, which integrates proprietary technology for a streamlined experience while ensuring privacy. PrestoDoctor has successfully hosted over 100 similar events. The festival will feature numerous vendors, food trucks, panels, music, and infield camping. PrestoDoctor is recognized as the top online medical marijuana doctor service and operates in multiple states. The company is engaged in telehealth and cannabis-related intellectual property. The press release also includes forward-looking statements and highlights potential risks involved in the cannabis industry.
Cannabis Sativa, Inc. (OTCQB:CBDS) announces the expansion of PrestoDoctor, its leading telemedicine service, to Louisiana, providing patients with access to online medical cannabis cards. With over 100,000 patients served across nine states, PrestoDoctor aims to enhance patient care by connecting them to licensed medical doctors for evaluations. CEO David Tobias anticipates substantial appointment growth and increased revenue from this launch, emphasizing the convenience and safety of their proprietary online service.
Cannabis Sativa (OTCQB:CBDS) announced that PrestoDoctor is now offering online medical cannabis card services in Texas. The COO, Rob Tankson, emphasized the service's accessibility for patients, while CEO David Tobias highlighted the potential for increased patient appointments and revenue. Established in 2015, PrestoDoctor has served over 100,000 patients across eight states and is praised for its patient satisfaction, holding more than 18,000 5-star reviews. The company is committed to providing compassionate care and education through telemedicine.
Cannabis Sativa Inc. (CBDS) announced a Letter of Intent to merge with MJ Harvest, Inc. (MJHI). This merger will transition CBDS's operations from telehealth to a vertically integrated cannabis business, consolidating operations in seven states. MJHI, which operates extraction and manufacturing facilities, holds significant cannabis licenses and brand partnerships. The merger terms include MJHI shareholders receiving 2.7 shares of CBDS for each MJHI share. Following the merger, MJHI will cease to exist, with CBDS becoming the surviving entity.
Cannabis Sativa, Inc. (CBDS) announced that PrestoDoctor will conduct on-site medical evaluations at the 8th Annual Pennsylvania Cannabis Festival on April 23-24, 2022. This event will take place at Renninger's Farmers Market in Kutztown, PA, featuring over 250 vendors. COO Rob Tankson emphasized the ease of obtaining medical cannabis recommendations during the festival, leveraging proprietary technology to streamline the process. PrestoDoctor has conducted over 100 similar events, maintaining high customer satisfaction ratings. CBDS focuses on telehealth, cannabis-related IP, and ancillary services.
Cannabis Sativa (OTCQB:CBDS) announced that CBGA, a compound in its patented Equadorian Sativa strain, effectively blocks the entry of COVID-19 into human cells, as reported in the Journal of Natural Products. The study indicates that CBGA must be taken orally for potential prevention and treatment of SARS-CoV-2. CEO David Tobias emphasized the importance of this finding and the ongoing research for effective product delivery protocols.